Baker Avenue Asset Management, LP Abb Vie Inc. Transaction History

Baker Avenue Asset Management, LP

$3.54 Billion
Q2 2024

A detailed history of Baker Avenue Asset Management, LP transactions in Abb Vie Inc. stock. As of the latest transaction made, Baker Avenue Asset Management, LP holds 101,286 shares of ABBV stock, worth $19.7 Million. This represents 0.49% of its overall portfolio holdings.

Number of Shares

101,286

Previous 91,265 10.98%

Holding current value

$19.7 Million

Previous $16.6 Million 4.53%

% of portfolio

0.49%

Previous 0.58%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	BUY	$154.79 - $180.76 $1.55 Million - $1.81 Million	10,021 Added 10.98%	101,286 $17.4 Million
Q1 2024 May 10, 2024	BUY	$159.82 - $182.1 $199,295 - $227,078	1,247 Added 1.39%	91,265 $16.6 Million
Q4 2023 Feb 13, 2024	BUY	$137.6 - $154.97 $975,721 - $1.1 Million	7,091 Added 8.55%	90,018 $14 Million
Q3 2023 Nov 14, 2023	BUY	$133.59 - $154.65 $349,471 - $404,564	2,616 Added 3.26%	82,927 $12.4 Million
Q2 2023 Aug 11, 2023	BUY	$132.51 - $164.9 $1.22 Million - $1.52 Million	9,242 Added 13.0%	80,311 $10.8 Million
Q1 2023 May 15, 2023	SELL	$144.61 - $166.54 $6.31 Million - $7.26 Million	-43,623 Reduced 38.03%	71,069 $11.3 Million
Q4 2022 Feb 13, 2023	SELL	$138.31 - $165.87 $699,710 - $839,136	-5,059 Reduced 4.22%	114,692 $18.5 Million
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $1.2 Million - $1.38 Million	8,977 Added 8.1%	119,751 $16.1 Million
Q2 2022 Aug 03, 2022	SELL	$137.62 - $174.96 $13.8 Million - $17.6 Million	-100,612 Reduced 47.6%	110,774 $17 Million
Q1 2022 May 16, 2022	SELL	$131.98 - $163.75 $5.77 Million - $7.15 Million	-43,688 Reduced 17.13%	211,386 $34.3 Million
Q4 2021 Feb 11, 2022	BUY	$107.43 - $135.93 $2.48 Million - $3.14 Million	23,113 Added 9.96%	255,074 $34.5 Million
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $869,394 - $986,893	8,171 Added 3.65%	231,961 $25 Million
Q2 2021 Aug 16, 2021	BUY	$105.21 - $117.21 $1.38 Million - $1.53 Million	13,073 Added 6.2%	223,790 $25.2 Million
Q1 2021 May 17, 2021	BUY	$102.3 - $112.62 $467,613 - $514,786	4,571 Added 2.22%	210,717 $22.8 Million
Q4 2020 Feb 17, 2021	BUY	$80.49 - $108.67 $2.26 Million - $3.05 Million	28,059 Added 15.76%	206,146 $22.1 Million
Q3 2020 Nov 16, 2020	BUY	$85.91 - $100.83 $791,145 - $928,543	9,209 Added 5.45%	178,087 $15.6 Million
Q2 2020 Aug 12, 2020	BUY	$73.37 - $98.18 $6.89 Million - $9.22 Million	93,926 Added 125.31%	168,878 $16.6 Million
Q1 2020 May 14, 2020	SELL	$64.5 - $97.79 $1.93 Million - $2.93 Million	-29,974 Reduced 28.57%	74,952 $5.71 Million
Q4 2019 Feb 14, 2020	SELL	$72.13 - $90.25 $254,402 - $318,311	-3,527 Reduced 3.25%	104,926 $9.29 Million
Q3 2019 Nov 15, 2019	BUY	$62.98 - $75.72 $1.5 Million - $1.8 Million	23,739 Added 28.02%	108,453 $8.21 Million
Q2 2019 Aug 14, 2019	BUY	$65.7 - $83.98 $4.49 Million - $5.74 Million	68,298 Added 416.05%	84,714 $6.16 Million
Q1 2019 May 15, 2019	SELL	$77.14 - $90.79 $1.11 Million - $1.31 Million	-14,418 Reduced 46.76%	16,416 $1.32 Million
Q4 2018 Feb 14, 2019	BUY	$77.85 - $96.01 $163,407 - $201,524	2,099 Added 7.3%	30,834 $2.84 Million
Q3 2018 Nov 15, 2018	SELL	$88.91 - $98.84 $740,620 - $823,337	-8,330 Reduced 22.47%	28,735 $2.72 Million
Q2 2018 Aug 14, 2018	BUY	$89.78 - $106.23 $291,605 - $345,035	3,248 Added 9.6%	37,065 $3.43 Million
Q1 2018 May 15, 2018	BUY	$92.01 - $123.21 $611,038 - $818,237	6,641 Added 24.44%	33,817 $3.2 Million
Q4 2017 Feb 14, 2018	BUY	$89.56 - $98.21 $837,027 - $917,870	9,346 Added 52.42%	27,176 $2.63 Million
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $127,266 - $162,558	1,822 Added 11.38%	17,830 $1.58 Million
Q2 2017 Aug 11, 2017	BUY	N/A	16,008	16,008 $1.16 Million

Others Institutions Holding ABBV

# of Institutions

3,694

Shares Held

1.27B

Call Options Held

13M

Put Options Held

9.79M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $344B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Avenue Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Avenue Asset Management, LP with notifications on news.

Account

Baker Avenue Asset Management, LP Abb Vie Inc. Transaction History